BTIG downgraded Valeritas Holdings (NASDAQ:VLRX) to “neutral” from “buy” and removed its previous $10 price target after the company reduced its fourth quarter revenue guidance due to a temporary supply disruption and...
Type 2 diabetes (T2D) patients achieved significantly lower average A1c levels and daily insulin usage when switching to Valeritas Holdings‘ (NASDAQ:VLRX) V-Go wearable insulin delivery device. A retrospective...
Valeritas Holdings’ (NASDAQ:VLRX) V-Go wearable insulin delivery device significantly lowered Type 2 diabetes (T2D) patients’ average A1C levels, compared with those using standard insulin treatment. Valeritas’ V-GoAL...